Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 17;14(9):1964.
doi: 10.3390/pharmaceutics14091964.

Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives

Affiliations
Review

Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives

Irene Paula Popa et al. Pharmaceutics. .

Abstract

Heart failure (HF) is a progressively deteriorating medical condition that significantly reduces both the patients' life expectancy and quality of life. Even though real progress was made in the past decades in the discovery of novel pharmacological treatments for HF, the prevention of premature deaths has only been marginally alleviated. Despite the availability of a plethora of pharmaceutical approaches, proper management of HF is still challenging. Thus, a myriad of experimental and clinical studies focusing on the discovery of new and provocative underlying mechanisms of HF physiopathology pave the way for the development of novel HF therapeutic approaches. Furthermore, recent technological advances made possible the development of various interventional techniques and device-based approaches for the treatment of HF. Since many of these modern approaches interfere with various well-known pathological mechanisms in HF, they have a real ability to complement and or increase the efficiency of existing medications and thus improve the prognosis and survival rate of HF patients. Their promising and encouraging results reported to date compel the extension of heart failure treatment beyond the classical view. The aim of this review was to summarize modern approaches, new perspectives, and future directions for the treatment of HF.

Keywords: angiotensin receptor–neprilysin inhibitor; autonomic modulation; cardiac myosin activation; heart failure; sodium-glucose co-transporter-2 inhibitors; soluble guanylate cyclase activator.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Pellicori P., Khan M.J.I., Graham F.J., Cleland J.G.F. New perspectives and future directions in the treatment of heart failure. Heart Fail. Rev. 2019;25:147–159. doi: 10.1007/s10741-019-09829-7. - DOI - PMC - PubMed
    1. Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. Eur. J. Heart Fail. 2020;22:1342–1356. doi: 10.1002/ejhf.1858. - DOI - PMC - PubMed
    1. Jones N.R., Roalfe A.K., Adoki I., Hobbs F.D.R., Taylor C.J. Survival of patients with chronic heart failure in the community: A systematic review and meta-analysis. Eur. J. Heart Fail. 2019;21:1306–1325. doi: 10.1002/ejhf.1594. - DOI - PMC - PubMed
    1. Correale M., Tricarico L., Fortunato M., Mazzeo P., Nodari S., Di Biase M., Brunetti N.D. New targets in heart failure drug therapy. Front Cardiovasc Med. 2021;8:665797. doi: 10.3389/fcvm.2021.665797. - DOI - PMC - PubMed
    1. D’Elia E., Iacovoni A., Vaduganathan M., Lorini F.L., Perlini S., Senni M. Neprilysin inhibition in heart failure: Mechanisms and substrates beyond modulating natriuretic peptides. Eur. J. Heart Fail. 2017;19:710–717. doi: 10.1002/ejhf.799. - DOI - PubMed